|
Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1068-1071, April 2026. <br/> 2026-04-20T07:00:00Z Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening Journal of Clinical Oncology, Volume 44, Issue 12, Page 1130-1138, April 2026. <br/> 2026-04-20T07:00:00Z Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 12, Page 1120-1129, April 2026. <br/> 2026-04-20T07:00:00Z CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1076-1082, April 2026. <br/> 2026-04-20T07:00:00Z Good Oncologist: Doctoring Lessons From the Art of Oncology Journal of Clinical Oncology, Volume 44, Issue 12, Page 1166-1173, April 2026. <br/> 2026-04-20T07:00:00Z VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1108-1119, April 2026. <br/> 2026-04-20T07:00:00Z Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update Journal of Clinical Oncology, Volume 44, Issue 12, Page 1145-1165, April 2026. <br/> 2026-04-20T07:00:00Z Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study Journal of Clinical Oncology, Volume 44, Issue 12, Page 1098-1107, April 2026. <br/> 2026-04-20T07:00:00Z Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) Journal of Clinical Oncology, Volume 44, Issue 12, Page 1083-1097, April 2026. <br/> 2026-04-20T07:00:00Z Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1139-1144, April 2026. <br/> 2026-04-20T07:00:00Z When the System Is the Treatment: Rethinking Nonpharmacologic Breakthroughs in Oncology Journal of Clinical Oncology, Volume 44, Issue 12, Page 1072-1075, April 2026. <br/> 2026-04-20T07:00:00Z Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases Journal of Clinical Oncology, Volume 44, Issue 12, Page 1174-1174, April 2026. <br/> 2026-04-20T07:00:00Z Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials Journal of Clinical Oncology, Volume 44, Issue 12, Page 1174-1175, April 2026. <br/> 2026-04-20T07:00:00Z Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases Journal of Clinical Oncology, Volume 44, Issue 12, Page 1175-1177, April 2026. <br/> 2026-04-20T07:00:00Z Reply to: “Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases,” “Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,” and “Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases” Journal of Clinical Oncology, Volume 44, Issue 12, Page 1177-1178, April 2026. <br/> 2026-04-20T07:00:00Z How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability Journal of Clinical Oncology, Volume 44, Issue 12, Page 1065-1067, April 2026. <br/> 2026-04-20T07:00:00Z |
Multifaceted Strategies for Hypertension Control in Low-Income Patients
New England Journal of Medicine, Volume 394, Issue 14, Page 1376-1387, April 9, 2026.
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia New England Journal of Medicine, Volume 394, Issue 14, Page 1388-1398, April 9, 2026.
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease New England Journal of Medicine, Volume 394, Issue 14, Page 1365-1375, April 9, 2026.
High-Dose Influenza Vaccine and Hospitalizations in Older Adults New England Journal of Medicine, Volume 394, Issue 14, Page 1453-1454, April 9, 2026.
Trends in Youth-Onset Type 2 Diabetes, 2013–2024 New England Journal of Medicine, Volume 394, Issue 14, Page 1451-1453, April 9, 2026.
More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism New England Journal of Medicine, Volume 394, Issue 14, Page 1456-1456, April 9, 2026.
Systems-Based Success for Hypertension New England Journal of Medicine, Volume 394, Issue 14, Page 1445-1446, April 9, 2026.
Silent Aspiration New England Journal of Medicine, Volume 394, Issue 14, April 9, 2026.
Case 10-2026: A 70-Year-Old Woman with a Racing Heart, Fatigue, and Dyspnea New England Journal of Medicine, Volume 394, Issue 14, Page 1431-1441, April 9, 2026.
From Clinic to Community — The EveryONE Project in Family Medicine New England Journal of Medicine, Volume 394, Issue 14, Page 1353-1354, April 9, 2026.
Leveraging School Systems as Data Partners to Advance Health Equity New England Journal of Medicine, Volume 394, Issue 14, Page 1355-1356, April 9, 2026.
Antiracism Pedagogy in Medical Education New England Journal of Medicine, Volume 394, Issue 14, Page 1358-1360, April 9, 2026.
Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults New England Journal of Medicine, Ahead of Print.
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure New England Journal of Medicine, Ahead of Print.
IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease New England Journal of Medicine, Ahead of Print.
Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism New England Journal of Medicine, Ahead of Print.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Ahead of Print.
A Phase 3 Trial of Brepocitinib in Dermatomyositis New England Journal of Medicine, Ahead of Print.
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial New England Journal of Medicine, Ahead of Print.
A Multicomponent Intervention to Improve Maternal Infection Outcomes New England Journal of Medicine, Ahead of Print.
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease New England Journal of Medicine, Ahead of Print.
Tuberculosis Cases and Deaths Averted by PEPFAR New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
Left Atrial Appendage Closure — Should Recommendations Be Expanded? New England Journal of Medicine, Ahead of Print.
Redefining Physiology in the Cardiac Catheterization Laboratory New England Journal of Medicine, Ahead of Print.
Intraosseous Abscess from Subacute Osteomyelitis New England Journal of Medicine, Ahead of Print.
Using Data to Inform Decision Making — Borrowing Limits for Graduate Nursing Students New England Journal of Medicine, Ahead of Print.
|
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
Among adults with persistent or chronic ITP, the incidence of adverse events with mezagitamab appeared to be similar to that with placebo. Mezagitamab treatment appeared to result in increased platelet counts at all three doses tested. 2026-04-09
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. 2026-04-09
Altering the Diet to Rewire Cancer A study in a mouse model of MYCN-amplified neuroblastoma implicates polyamine levels in affecting the makeup of the proteome and biologic characteristics of the tumor. 2026-04-09
Necrolytic Migratory Erythema An 83-year-old woman with worsening type 2 diabetes presented with a 6-month history of painful rash. Hyperpigmented plaques with coalescing erosions and blisters were seen. Abdominal CT revealed a mass in the tail of the pancreas. 2026-04-09
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat sickle cell disease. 2026-04-02
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. 2026-04-02
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat transfusion-dependent β-thalassemia. 2026-04-02
More Options for Gene Editing in Hemoglobinopathies Transfusion-dependent β-thalassemia and sickle cell disease, both characterized by defective hemoglobin synthesis, are the most common monogenic diseases worldwide. Each year, approximately 60,000 infants are born with transfusion-dependent β-thalassemia, and 500,000 infants receive a diagnosis of sickle cell disease.1,2 Historically, patients with these disorders have rarely survived beyond... 2026-04-02
Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy Although bladder preservation with trimodal therapy is a category 1 recommendation in the National Comprehensive Cancer Network (NCCN) guidelines for appropriately selected patients with muscle-invasive bladder cancer, the real-world adoption of this type of therapy in the United States remains disappointingly low. Contemporary data suggest that only half the patients... 2026-04-02
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease In this study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. 2026-04-01
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer In a trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. 2026-03-26
Brief Report: Prime Editing for p47phox-Deficient Chronic Granulomatous Disease In this study, gene editing with a prime editor was used to treat two persons with chronic granulomatous disease caused by a small deletion in the gene NCF1. 2026-03-26
Corporate Vectors of Chronic Disease — Using Internal Industry Documents to Craft Counterstrategies Corporations that make and market health-harming products are a primary vector for the global increase in mortality related to noncommunicable diseases. Research using internal industry documents can help. 2026-03-26
ATOMIC Energy — Biomarker-Bespoke Adjuvant Therapy for Colon Cancer In countries with organized screening programs for colorectal cancer, 25% of patients who receive a diagnosis have stage III disease with involved regional lymph nodes. Surgery cures only half these patients, and 6 months of fluoropyrimidine-based adjuvant chemotherapy (e.g., intravenous fluorouracil or oral capecitabine) has been the cornerstone of treatment... 2026-03-26
Genetic Medicine — Primed and Ready Immunodeficiency chronic granulomatous disease (CGD) is a rare disorder characterized by defects in a multiprotein complex that generates superoxide in phagocytic cells.1 Recurrent infections and formation of granulomas are hallmarks of X-linked and autosomal-recessive CGD, which is caused by variants in genes encoding individual subunits. As a monogenic... 2026-03-26
Case 9-2026: A 12-Year-Old Girl with Altered Mental Status and Hypoglycemia A 12-year-old girl was admitted to the hospital with altered mental status and abdominal distention. The blood glucose level was 30 mg per deciliter. Symptoms abated with glucose administration. A diagnosis was made. 2026-03-26
Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries In an evaluation in low- and middle-income countries involving 95 patients with chronic myeloid leukemia who had deep remission for more than 1 year, 79% remained in treatment-free remission after imatinib discontinuation. 2026-03-26
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. 2026-03-25
The Dismantling of Environmental Protections — A Grave Threat to America’s Health The Trump administration’s wide-ranging actions to dismantle U.S. environmental regulations will cause long-lasting health harms, disproportionately affecting low-income and other vulnerable groups. 2026-03-25
Prehospital Whole Blood in Traumatic Hemorrhage — a Randomized Controlled Trial Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. 2026-03-17
|
|
| ||
|
[Editorial] The promise of telesurgery in oncology
In early 2026, 62-year-old Gibraltar resident Paul Buxton had a successful robotic prostatectomy to treat his prostate cancer. His surgeon was 2400 km away in London, UK. In mid-2025, a surgeon in Florida, USA, performed the same surgery on a patient in Angola, Africa—the longest distance telesurgery recorded to date. Once the realm of science fiction, telesurgery is rapidly transforming surgical oncology, with the potential to bridge health equity gaps and overcome health-system barriers, facilitating access to high-quality surgical care in remote and underserved regions and relieving global workforce shortages. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer For more than a decade, immune checkpoint inhibitors (ICIs) have played a central part in the treatment landscape of advanced non-small-cell lung cancer (NSCLC).1 These therapies have improved survival both as monotherapy and in combination with chemotherapy and altered expectations for patients with metastatic disease. Yet their benefit is not universal. A substantial proportion of patients (∼18%) derive little or no clinical improvement, and some experience rapid deterioration with primary resistance. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] KRASG12C inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path KRAS has long been regarded as an indomitable oncogenic driver which defines a distinct and therapeutically elusive class of solid tumours. The recent advent of direct KRAS inhibitors has fundamentally altered the drug development landscape of KRAS-mutated tumours, including non-small-cell lung cancer (NSCLC). The first entrants in this class used a unique mechanism of action which inhibited KRASG12C by irreversibly binding to its inactive GDP-bound conformation at the switch-II binding pocket (KRASG12C[OFF] inhibitors). Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Antibody–drug conjugates for bladder sparing: lessons from SURE-02 trial Historically, perioperative cisplatin based neoadjuvant therapy has remained the gold standard for muscle-invasive bladder cancer. In the past 5 years, several practice changing trials have enabled the incorporation of immune checkpoint inhibitors in the perioperative setting for muscle-invasive bladder cancer. The phase 3 NIAGARA study led to the approval of durvalumab in combination with gemcitabine or cisplatin followed by adjuvant immune checkpoint inhibitor monotherapy.1 The CheckMate-274 and AMBASSADOR trials showed improved outcomes in patients treated with adjuvant immune checkpoint inhibitors. Fri, 27 Feb 2026 20:00:01 +0000
[Comment] Sentinel lymph node procedure in the era of new melanoma therapies Since 1992, the surgical treatment for melanoma has substantially changed,1 and in clinically negative nodal basin, elective lymph node dissection has been overtaken by the sentinel node biopsy (SNB) followed by complete lymph node dissection in the case of positivity to SNB at the histopathological report. Many different studies have examined these methods, looking at specific subclinical features such as micro-metastases or macro-metastases,2 SNB tumour burden,3 number of SNBs, number of positive non-sentinel lymph nodes, and number of excised non-sentinel lymph nodes. Thu, 05 Mar 2026 20:55:01 +0000
[Comment] Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in patients with oligometastatic hormone-sensitive prostate cancer (HSPC).1 By showing that 177Lu-PSMA-617 can significantly delay disease progression while maintaining a favourable safety profile, the BULLSEYE trial expands the therapeutic horizon of PSMA-targeted radioligand therapy beyond its established role in metastatic castration-resistant prostate cancer (mCRPC). Wed, 01 Apr 2026 00:00:00 -0700
[Comment] B7-H3 antibody–drug conjugate turning immune evasion into vulnerability Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy in several indications owing to their favourable balance between efficacy and tolerability. Trastuzumab deruxtecan exemplifies this paradigm shift, having achieved regulatory approvals across multiple HER2 (ERBB2)-expressing or HER2-mutated solid tumours, including breast, gastric, and non-small-cell lung cancers (NSCLCs). Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Implications of indiscriminate testing for cancer susceptibility genes Expansion of genetic testing to the general population is one of the ambitions of the UK Government's 2025 10-year Health Plan for England, as part of a strategy for transition from “sickness to prevention”.1 Identification of individuals at increased cancer risk due to pathogenic variants in cancer susceptibility genes, leading to targeted screening and prioritisation of risk reduction strategies is one potential benefit of this approach. However, there are many outstanding questions about the impact on health-care services. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] NICE 2026 guideline for the diagnosis and management of kidney cancer Kidney cancer is the sixth most common cancer in adults in the UK, with approximately 13 900 new cases every year.1 Kidney cancer incidence rates have almost doubled since the 1990s and are projected to rise further by 2040.2 5-year relative survival for kidney cancer in the UK is below the European average,3 and there is wide variation in provision of kidney cancer care in England and Wales.4 If found early, kidney cancer can be cured, but early diagnosis is challenging as most people (87%) in the UK with stage 1a disease are diagnosed incidentally, having no relevant symptoms. Thu, 19 Mar 2026 12:00:01 +0000
[Correspondence] ALND after neoadjuvant chemotherapy: a call for caution We read with interest the Article by Giacomo Montagna and colleagues1 evaluating oncological outcomes in patients with residual nodal micrometastatic disease (ypN1mi) following neoadjuvant systemic therapy. Although the study contributes important data on axillary management, the recommendation favouring completion axillary lymph node dissection (ALND) in patients with triple-negative breast cancer warrants cautious interpretation given key limitations and conflicting evidence. Wed, 01 Apr 2026 00:00:00 -0700
[Correspondence] ALND after neoadjuvant chemotherapy: a call for caution We read with great interest the Article by Giacomo Montagna and colleagues,1 which addresses a pivotal question in contemporary breast cancer care—if axillary lymph node dissection (ALND) can be safely omitted in patients with residual micrometastases (ypN1mi) after neoadjuvant chemotherapy. Their multinational cohort provides much-needed outcome data to inform surgical de-escalation strategies. However, the significantly higher axillary recurrence rate observed in patients with triple-negative breast cancer who did not undergo ALND (8·7% [95% CI 4·4–15·0] vs 2·4% [0·7–6·5]; p=0·018) warrants careful interpretation before this finding influences clinical practice. Wed, 01 Apr 2026 00:00:00 -0700
[Correspondence] ALND after neoadjuvant chemotherapy: a call for caution – Authors' reply We have read the Correspondence from Kefah Mokbel, Fady Sourial, and their colleagues with interest, thank them for their comments, and welcome the opportunity to clarify the points they raise. Among 1585 patients with residual nodal micrometastases (ypN1mi) following neoadjuvant chemotherapy, our study failed to show a short-term oncological benefit from axillary lymph node dissection (ALND), with the exception of patients with triple-negative breast cancer (284 [18%]). The rate of axillary recurrence among the 127 patients who had triple-negative breast cancer but did not undergo completion ALND was higher than it was among the 157 who did (8·7% [95% CI 4·4–15·0] vs 2·4% [0·7–6·5], p=0·018). Wed, 01 Apr 2026 00:00:00 -0700
[Correspondence] From reliability to implementable toxicity policy in PRO-informed CTCAE Lisa M Wintner and colleagues show that giving clinicians access to EORTC patient-reported outcome (PRO) data during assessment with Common Terminology Criteria for Adverse Events (CTCAE) significantly increased inter-rater reliability for 13 of 17 symptomatic adverse events, with the largest gains in cognitive and psychological domains.1 This pragmatic multinational trial provides timely evidence for integrating PROs into safety assessment workflows. Wed, 01 Apr 2026 00:00:00 -0700
[Correspondence] From reliability to implementable toxicity policy in PRO-informed CTCAE – Authors' reply We thank Jiale Chen and Xiaoyuan Xu for suggesting presentation of absolute risks of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 and above, and 3 and above, symptomatic adverse events and corresponding risk differences between study groups to illustrate the added value of PRO data for adverse event identification. For each adverse event, we calculated the proportion of patients with the highest grade 2 and 3 or above per group, using the higher of the two available ratings (worst toxicity reported). Wed, 01 Apr 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 233–42 Wintner LM, Sztankay M, Abdel-Razeq H, et al. Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial. Lancet Oncol 2026; 27: 233–42—In this Article, the final sentence in the Findings of the Summary should have read “There was no significant difference for pain, diarrhoea, fatigue, and peripheral sensory neuropathy.” In the figure, the box noting exclusions from the intervention group should have read “28 had incomplete CTCAE assessments”. Wed, 01 Apr 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 413 Sharma DC. India introduces human papillomavirus vaccination. Lancet Oncol 2026; 27: 413—In this News, the in-text affiliations for Ravi Mehrotra and Soumya Swaminathan have been corrected. These corrections have been made to the online version as of March 30, 2026, and the printed version is correct. Wed, 01 Apr 2026 00:00:00 -0700
[News] Jordan launches new national cancer strategy On Feb 15 (commemorating the World Childhood Cancer Day), Jordan announced three linked initiatives: a National Cancer Control Strategy 2026–2030, six national paediatric cancer clinical guidelines, and its entry into the Global Platform for Access to Childhood Cancer Medicines. The event was jointly organised by the Ministry of Health and WHO under the patronage of Princess Ghida Talal of the King Hussein Cancer Foundation and King Hussein Cancer Center (KHCC; Amman, Jordan). The event also included participation of civil society organisations supporting patients with cancer (among panellists), to foster meaningful engagement of patients in line with WHO guidance. Thu, 26 Feb 2026 23:30:01 +0000
[News] Cancer prevention, treatment, and palliative care in South Sudan On Feb 26, 2026, WHO announced that South Sudan's leadership had signalled renewed political attention to cancer control after Vice President, Josephine Lagu Yanga, met with WHO officials in Juba to discuss strengthening prevention, screening, treatment, and palliative care. The talks came as the country begins to mobilise a more coordinated response to cancer. Thu, 05 Mar 2026 23:30:01 +0000
[News] Rare Cancers Bill to become law in UK On Feb 27, 2026, lawmakers in the UK voted to sign into law the Rare Cancers Bill. The bill was proposed by Scott Arthur, a Member of Parliament for the ruling Labour Party based in Scotland, and a medical doctor. The bill will help accelerate research innovation to improve treatments and survival for rare cancers, including brain tumours and pancreatic cancer. The new law will take effect just as the UK has launched two major plans—The National Cancer Plan for England, and The England Rare Diseases Action Plan 2026. Thu, 05 Mar 2026 23:30:00 +0000
[News] Canada invests in cancer prevention research The Government of Canada and five partner organisations have committed more than CA$41 million to fund 19 cancer prevention research teams over 5 years. The announcement was made on Feb 26, 2026, at Princess Margaret Cancer Centre in Toronto by Marjorie Michel, Canada's Minister of Health. It is the single largest investment in cancer prevention research ever led by the Canadian Institutes of Health Research (CIHR). Thu, 05 Mar 2026 23:30:01 +0000
[News] India introduces human papillomavirus vaccination On Feb 28, 2026, Indian Prime Minister Narendra Modi unveiled a national campaign to promote human papillomavirus (HPV) vaccination to prevent cervical cancer. During the 90-day drive, 11·5 million girls aged 14 years will be administered the vaccine for free at government-run health facilities across the country. “This is the largest free HPV vaccination campaign in history”, said WHO Director-General Tedros Adhanom Ghebreyesus (WHO, Geneva, Switzerland). After the current campaign ends, the Indian health ministry will integrate the HPV vaccine into the Universal Immunisation Programme (UIP) and make it available at government health facilities during routine immunisation days, Health Minister Jagat Prakash Nadda (New Delhi, India) announced while addressing a virtual press conference, along with Ghebreyesus, on March 5. Thu, 12 Mar 2026 23:30:00 +0000
[News] 2026 Society of Surgical Oncology Annual Meeting Presenting on behalf of a large international team, Martin Heidinger (DBM Hebelstrasse, Basel, Switzerland), showed results from a preplanned analysis of the TAXIS/OPBC-03 phase 3 trial. Axillary lymph node dissection (ALND) is the standard of care for patients with node-positive breast cancer after neoadjuvant chemotherapy or upfront surgery. The use of tailored axillary surgery (TAS) to reduce axillary tumour burden to a degree where radiotherapy might be able to control the remaining extent of disease could reduce morbidity. Thu, 12 Mar 2026 23:30:01 +0000
[News] US EPA proposes easing ethylene oxide emission standards The US Environmental Protection Agency (EPA) proposed changes to rollback safeguards against air emissions of ethylene oxide (EtO), a highly carcinogenic gas used to sterilise about half of all medical devices in the USA. Announced March 17, 2026, the proposed changes would, among other things, relax round-the-clock emissions monitoring requirements for about 90 commercial sterilisation facilities. Thu, 19 Mar 2026 23:30:03 +0000
[News] Thailand's plans to draft Cancer Act The Public Health Ministry in Thailand has planned to draft the country's first National Cancer Act, as new cancer cases and deaths from cancer remain high in the country. Thu, 19 Mar 2026 23:30:01 +0000
[News] Conflict disrupts global supply chains for cancer medicines Disruptions to pharmaceutical transport routes linked to the escalating conflict in the Middle East are raising alarms about the fragility of cancer medicine supply chains in low-income and middle-income countries, particularly across Africa. Routes commonly used to carry temperature-sensitive medicines—including chemotherapy drugs and other oncology supplies—have been affected as airlines and shippers avoid conflict zones, increasing costs and delaying deliveries. For patients already navigating fragile health systems, even short interruptions can have serious consequences. Thu, 19 Mar 2026 23:30:00 +0000
[News] 41st Annual European Association of Urology Congress 2026 Improved risk stratification in prostate testing could ensure effective resource allocation, according to results from the OPT Stockholm3 study. In the population-based study, Ugo Falagario and colleagues (University of Foggia, Foggia, Italy) assessed whether reflex testing with Stockholm3 after PSA testing could reduce the proportion of men referred for MRI versus a PSA-only pathway. The OPT Stockholm3 pathway invited all men in the Region Stockholm Gotland in 2024 (born in 1974; Stockholm3 testing if PSA ≥2 ng/mL and if Stockholm3 ≥15 MRI) and 2023 (born in 1973; MRI if PSA ≥3 ng/mL). Thu, 19 Mar 2026 23:30:01 +0000
[Perspectives] Spaceflight as a cancer research catalyst As we venture further into space and increasingly use low Earth orbit for in-space manufacturing, the potential for the development of innovative technologies appears to be infinite. For these discoveries, led by the National Aeronautics and Space Administration (NASA), international space agencies, and commercial companies, the International Space Station (ISS) provides a transformative research platform 250 miles above us in low Earth orbit. Although it might not be immediately obvious how research done hundreds of miles above our planet could be used to improve life terrestrially, studies in low Earth orbit have revealed accelerated stem-cell ageing; immune dysfunction; and genomic, epigenomic, and transcriptomic instability that set the stage for cancer initiation and progression. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial Benmelstobart plus anlotinib showed longer progression-free survival than pembrolizumab plus placebo and no unexpected safety signals were reported, suggesting benmelstobart plus anlotinib as a potential first-line option in driver gene-negative, PD-L1-positive, advanced NSCLC. Longer term follow-up is needed to establish effects on overall survival. Tue, 10 Mar 2026 23:30:01 +0000
[Articles] Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study Perioperative sacituzumab govitecan plus pembrolizumab revealed a promising clinical complete response rate, without the occurrence of grade 4 or higher adverse events, allowing a bladder preservation with sustained remission in approximately 40% of patients. Fri, 27 Feb 2026 20:00:01 +0000
[Articles] Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis This meta-analysis showed that people with melanoma who underwent SNB had a significantly reduced risk of death from melanoma and recurrence compared with those who did not. These findings are consistent with the only published randomised controlled trial and were robust on sensitivity analyses, indicating that SNB confers true survival and recurrence benefits. Thu, 05 Mar 2026 20:55:01 +0000
[Articles] [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 177Lu-PSMA-617 showed promising response rates and delayed disease progression in patients with oligometastatic HSPC in this trial. In addition, most treatment-related adverse events were low grade. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study Multicycle [177Lu]Lu-PSMA-617 and pembrolizumab showed encouraging activity with manageable toxicity that was consistent with [177Lu]Lu-PSMA-617 or pembrolizumab, and the combination might provide durable clinical benefit in a subset of patients. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study We present new risk nomograms by PROMISE along with a simple table to prognosticate 3-year, 5-year, and 7-year overall survival in prostate cancer. PROMISE and PPP3 assessments are freely available online for global implementation. Mon, 09 Mar 2026 23:30:01 +0000
[Articles] Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial The maximum tolerated dose was not reached with ifinatamab deruxtecan; however, one death due to treatment-related interstitial lung disease highlights the importance of prompt evaluation and careful management of patients who develop interstitial lung disease. Promising antitumour activity was observed across various solid tumours. These findings support further evaluation of ifinatamab deruxtecan in randomised controlled trials. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Interpretation of constitutional cancer predisposition gene variants in 14 765 individuals in the 100 000 Genomes Project cancer arm: a retrospective cohort analysis Understanding the frequency and nature of variants in cancer predisposition genes is important for planning of clinical services. Our analysis highlights the implications of more expansive genetic testing and the variant interpretation considerations necessary to yield benefit and avoid harm (eg, unnecessary surveillance) for patients. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study These findings show that AI applied to routine histopathology can serve as a practical and scalable tool for guiding chemotherapy decisions in hormone receptor-positive, HER2-negative, early breast cancer. This approach has the potential to reduce unnecessary chemotherapy and broaden access to precision oncology, particularly in resource-limited settings where genomic testing remains unavailable or unaffordable. Wed, 11 Mar 2026 23:30:01 +0000
[Policy Review] Principles of cytoreductive surgery for primary and metastatic peritoneal malignancies—the PSOGI–ESGO–ISSPP Lyon consensus Complete macroscopic resection is the key objective of cytoreductive surgery for peritoneal malignancy. However, heterogeneity in terminology and operative technique persists across centres and between surgical and gynaecological disciplines. This study sought to establish international consensus on the nomenclature of cytoreductive surgery procedures, key technical principles of peritonectomy procedures and visceral resections, and management of regional lymph nodes in the context of peritoneal malignancy. Wed, 01 Apr 2026 00:00:00 -0700
[Policy Review] Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology Vaccine-preventable infections remain a major cause of morbidity and mortality in patients with cancer. The updated guideline for anti-infective vaccination strategies in patients with cancer of the German Society of Hematology and Medical Oncology Infectious Diseases Working Group was developed by a guideline panel of experts in internal medicine, haematology, medical oncology, and infectious diseases. For previously covered vaccinations, we included all publications in patients with cancer starting from 2017, as this was the data cutoff for the previous guideline, and for newly included vaccines all publications were reviewed. Wed, 01 Apr 2026 00:00:00 -0700
[Policy Review] Advancing cancer equity in seven high-income countries: an analysis of policy levers and National Cancer Control Plans Persistent inequities in cancer outcomes remain a defining challenge for global health systems, including in high-income countries. Despite advances across prevention, early detection, treatment, and survivorship, disparities persist, reflecting entrenched social and structural inequities. While equity is increasingly articulated within national and global cancer agendas, comparative analysis of how equity is conceptualised and operationalised in national cancer control planning remains limited. Wed, 01 Apr 2026 00:00:00 -0700
[Policy Review] A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR) Patient-reported outcomes (PROs) are increasingly recognised for their role in assessing tolerability in dose-finding oncology trials (DFOTs). However, analysis and reporting of PRO data within DFOTs are often unclear and inconsistent. OPTIMISE-AR (Incorporating Patient-Reported Outcomes in Dose-Finding Trials–Analysis Recommendations) establishes a practical toolkit supporting the statistical analysis, visualisation, and reporting of PRO data within DFOT publications. International, multidisciplinary, cross-sector statistical analysis and data visualisation working groups identified analytical and visualisation approaches for PROs data, addressing key DFOT PRO research objectives. Tue, 17 Mar 2026 11:15:00 +0000
[Clinical Picture] New subcutaneous nodules and joint pain in a patient with pancreatic cancer A 51-year-old man with advanced pancreatic cancer presented to General Hospital of Southern Theater Command (Guangzhou, China) in December, 2025, with a 3-week history of rapidly spreading, painful subcutaneous nodules (figure A), and bilateral knee pain. He was on maintenance oral tegafur after initial response to FOLFIRINOX. His knee pain, initially managed as gout given his history, was unresponsive to treatment. Skin biopsy revealed lobular panniculitis with neutrophilic infiltration and anucleate necrotic adipocytes (ghost cells), consistent with pyogenic panniculitis (figure B). Wed, 01 Apr 2026 00:00:00 -0700
|
|
[Editorial] From diagnosis to equitable care in bleeding disorders
Up to three-quarters of people with haemophilia worldwide are estimated to be undiagnosed, with an even bigger gap predicted for other bleeding disorders. This astonishing statistic underlies the focus of this year's World Haemophilia Day, on April 17, on diagnosis: a first step to care. Even when people are diagnosed, there are substantial inequalities in access to treatment and bleeding prophylaxis in many parts of the world. 2026 could mark a crucial year for turning the tide on these issues, with the recent approval of a World Health Assembly (WHA) resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, which will be presented at the 79th WHA on May 18–23, 2026, for final adoption. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Updated anaemia estimates: implications for global monitoring In 2024, WHO updated haemoglobin thresholds and revised the adjustments for altitude and smoking.1 The earlier elevation adjustments were established in 1989 and were based on a demographically limited subset of populations and did not adequately represent the diversity of global populations. The 2024 updated elevation adjustment was based on the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project, which leverages multinational surveys with broader geographical and demographic representation than previous methods. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Maintenance intensification after autologous HSCT: refining selection In The Lancet Haematology, Dominik Dytfeld and colleagues1 report the findings from the phase 3 ATLAS trial, comparing carfilzomib–lenalidomide–dexamethasone with lenalidomide alone as maintenance therapy after autologous haematopoietic stem-cell transplantation (HSCT) in patients with newly diagnosed multiple myeloma. Lenalidomide monotherapy has long been the global standard of care in this setting, based on consistent improvements in progression-free survival and overall survival.2 With a median follow-up of nearly 6 years, carfilzomib–lenalidomide–dexamethasone maintenance significantly improved 4-year progression-free survival (67·5% [95% CI 56·2–76·4] vs 38·0% [27·6–48·2]; hazard ratio 0·46 [95% CI 0·30–0·70]) with a manageable safety profile. Wed, 11 Mar 2026 23:30:01 +0000
[Correspondence] Patient selection and treatment sequencing in RESMAIN The RESMAIN trial by Rudolf Stadler and colleagues, published in The Lancet Haematology, showed that resminostat maintenance therapy significantly prolonged median progression-free survival (median 8·3 months, 95% CI 4·2–15·7) compared with placebo (4·2 months, 2·8–6·4) in patients with advanced-stage mycosis fungoides or Sézary syndrome.1 These diseases are characterised by repeated cycles of remission and relapse. Therefore, progression-free survival does not carry the same clinical implications as in acute leukaemia or solid tumours, in which relapse is often associated with worse survival. Wed, 01 Apr 2026 00:00:00 -0700
[Correspondence] Patient selection and treatment sequencing in RESMAIN – Author's reply I would like to thank Takashi Miyachi and colleagues for their Correspondence regarding the RESMAIN trial. The most prevalent forms of cutaneous T-cell lymphoma are mycosis fungoides and its variants, as well as Sézary syndrome. According to the current guidelines, in the early stages of the disease, the recommended therapeutic approach is based on skin-directed therapies. In more advanced stages of the disease, the recommended treatment involves primarily non-toxic systemic drugs, such as pegylated interferon, bexarotene, and combinations with radiotherapy or extracorporeal photopheresis. Wed, 01 Apr 2026 00:00:00 -0700
[Corrections] Correction to Lancet Haematol 2026; 13: e169–80 Olíva EN, Cottone F, Unni S, et al. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial. Lancet Haematol 2026; 13: e169–80—In figure 2 of this Article, the two groups were incorrectly labelled “Q+stdCT” and “Q+stdCT” instead of “Q+stdCT” and “P+stdCT”. This correction has been made as of April 2, 2026. Wed, 01 Apr 2026 00:00:00 -0700
[Corrections] Correction to Lancet Haematol 2026; published online March 11. https://doi.org/10.1016/S2352-3026(26)00064-5 Perrot A, Frenzel L. Maintenance intensification after autologous HSCT: refining selection. Lancet Haematol 2026; published online March 11. https://doi.org/10.1016/S2352-3026(26)00064-5—In this Comment, the title should have been Maintenance intensification after autologous HSCT: refining selection. This correction has been made as of March 19, 2026. Thu, 19 Mar 2026 23:30:01 +0000
[Corrections] Correction to Lancet Haematol 2026; 13: e241–53 Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol 2026; 13: e241–53—Anna Puła's affiliations should have been “Medical University of Lodz, Lodz, Poland” and “University of Chicago, Chicago, IL, USA”. Agnieszka Druzd-Sitek's and Prof Jan Walewski's affiliation should have been “Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw”. Wed, 01 Apr 2026 00:00:00 -0700
[News] WHO resolution pushes for global equity in haemophilia care WHO has adopted a resolution to advance health equity for people with haemophilia and other bleeding disorders. Led by Armenia and co-sponsored by 12 countries across Europe, Asia, Africa, and the Americas, the resolution was approved by the WHO Executive Board (EB158) meeting on Feb 3, 2026, and aims to improve access to care and treatment worldwide. Armen Melkonyan, Head of International Relations at the Ministry of Health in Armenia, presented the resolution, which seeks to establish an international framework to improve care and treatment for people with haemophilia and other bleeding disorders. Wed, 01 Apr 2026 00:00:00 -0700
[In Focus] Concomitant or sequential lower intensity triplet therapy in AML Jayastu Senapati and Naval G Daver Wed, 01 Apr 2026 00:00:00 -0700
[In Focus] Scientific progress in the shadow of regional instability I write on a day of unexpected personal and professional convergence. This past week, I spent long days in strategic discussions on enabling cell and gene therapy programmes—expanding access to advanced therapeutics and building infrastructure so that patients in our region might benefit from innovation at home rather than waiting for it to become available elsewhere. The work was forward-looking and ambitious. Yet I awoke today to news and sounds of interception explosions that, for the first time, felt unexpectedly and uncomfortably close to my new home, the United Arab Emirates. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial Deucrictibant significantly reduced the severity of hereditary angioedema attacks compared with placebo; these results support continued investigation of antagonism of the bradykinin B2 receptor with an orally available agent as a potentially effective approach, with a safety profile similar to placebo, for on-demand treatment. Thu, 19 Mar 2026 23:30:03 +0000
[Articles] Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial To the best of our knowledge, this trial provides the first clinical evidence and proof-of-concept for bradykinin B2 receptor antagonism as a therapeutic approach for the prevention of hereditary angioedema attacks and supports further investigation of oral deucrictibant for bradykinin-mediated angioedema. Thu, 19 Mar 2026 23:30:01 +0000
[Articles] Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990–2023: a population-based modelling study Understanding the effect of anaemia requires unbiased and comparable estimates of anaemia burden. To our knowledge, we produced the first set of global estimates of anaemia burden by location, year, age, and sex using the WHO 2024 elevation adjustment method and compared them with estimates using the previous method. Policy makers should consider this modification when designing interventions to manage and prevent anaemia, particularly in regions most affected by changes in elevation adjustment. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial The enhanced efficacy of carfilzomib–lenalidomide–dexamethasone treatment following autologous HSCT in patients with newly diagnosed multiple myeloma, assessed within a framework of de-escalation based on MRD status and individual risk, supports strategies for maintenance therapy intensification in this setting. Wed, 11 Mar 2026 23:30:02 +0000
[Viewpoint] Building safeguards for gene therapy in haemophilia Haemophilia care has progressed through successive therapeutic revolutions, from plasma-derived and recombinant factor replacement to extended half-life products and non-factor therapies. The introduction of gene therapy, with currently approved approaches using adeno-associated viral vectors to deliver functional copies of the factor VIII or IX gene into hepatocytes, now represents the next paradigm shift: a one-time, irreversible intervention designed to restore endogenous factor production. Although early results are promising, the experience of transfusion transmitted infections reminds the haemophilia community that innovation must be matched by vigilance, transparency, and accountability. Tue, 10 Mar 2026 22:30:01 +0000
[Viewpoint] Balancing the benefits and risks of rebalancing coagulation in haemophilia Rebalancing agents represent a novel therapeutic class in haemophilia, designed to restore the deficient thrombin generation that underlies bleeding. Unlike factor replacement or factor VIII mimetic therapies, rebalancing agents act by downregulating natural anticoagulants. By partially inhibiting these physiological brakes of coagulation, they induce a controlled and reversible procoagulant shift. These agents have shown clinically meaningful reductions in bleeding rates across both haemophilia A and B, including in patients with inhibitors. Tue, 10 Mar 2026 23:30:01 +0000
|
|
| ||
|
Rescue gone rogue: the ERCC6L2 syndrome and TP53 mutations
Volume 147, Issue 15
April 9 2026 Ibrutinib: 10 years and counting Volume 147, Issue 15
April 9 2026 Targeted therapy in early-stage classical Hodgkin lymphoma Volume 147, Issue 15
April 9 2026 Digging deep for the roots of lymphoma Volume 147, Issue 15
April 9 2026 Das not enough in CBF AML Volume 147, Issue 15
April 9 2026 Heating up coagulation through necroptosis Volume 147, Issue 15
April 9 2026 GVHD fails the acid test Volume 147, Issue 15
April 9 2026 Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease Germ line homozygous loss-of-function mutations in ERCC6L2 cause bone marrow failure (BMF) with a high risk of transformation to myelodysplastic syndromes and acute myeloid leukemia. The leukemias are typically categorized as acute erythroid leukemias, which almost uniformly (>90%) harbor biallelic TP53 mutations. In a Plenary Paper, Schimmer and colleagues provide insights to disease evolution by demonstrating that p53 loss can rescue BMF phenotypes caused by biallelic mutations in ERCC6L2, but at the cost of profound genome instability, increasing DNA damage and leading to the onset of aggressive erythroid leukemia.
Volume 147, Issue 15
April 9 2026 Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine Over the last 5 decades, the transplantation of hematopoietic stem cells (HSCs) has been extensively used for the treatment of inherited blood disorders and blood malignancies. Castiglioni, Piussi, and Ditadi lay out a comprehensive review of embryonic HSC development, underscoring ontogeny and master regulators, and they summarize recent discoveries and advances in the field of in vitro de novo generation and differentiation protocols of HSCs for basic research and clinical applications.
Volume 147, Issue 15
April 9 2026 How I approach clinical ethics consultation in hematology The care of patients with complex hematological disorders may raise difficult ethical issues. In this How I Treat article, Marron, Semler, and Abel tackle this complicated topic using 3 clinical vignettes that provide a framework for a practical and informed approach to these situations, effectively showing that resolving these complicated ethical questions is critical for high-quality clinical hematology care.
Volume 147, Issue 15
April 9 2026 A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study The first-in-class covalent Bruton tyrosine kinase inhibitor ibrutinib has transformed chronic lymphocytic leukemia (CLL) therapy over the last 15 years. Itsara and colleagues report 10-year follow-up of the treatment of CLL with ibrutinib in 84 patients, demonstrating a median progression-free survival of 9 years in frontline CLL and 4.1 years in relapsed CLL. Survival outcomes in patients with TP53 mutations were improved compared to those in historic controls but still shorter than those in patients without TP53 aberrations. This study underscores the remarkable durability and depth of response achieved with ibrutinib in CLL.
Volume 147, Issue 15
April 9 2026 Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with chemotherapy with or without radiation therapy. Abramson and colleagues report the efficacy and safety of the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) and the anti-PD1 antibody nivolumab in combination with doxorubicin and dacarbazine chemotherapy (AN+AD) for the treatment of nonbulky cHL in 154 patients. Four cycles of AN+AD achieve a complete response rate of 92% (95% confidence interval [CI], 86.0%-95.4%) and an estimated 2-year progression-free survival rate of 97% (95% CI, 92.0%-98.8%). These encouraging data support the use of BV and nivolumab in regimens for patients with early-stage cHL.
Volume 147, Issue 15
April 9 2026 Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma Although the association between clonal hematopoiesis (CH) and myeloid malignancy is well established, the relationship between CH and lymphoid malignant disease is not well understood. Wiegand and colleagues evaluated the prevalence and hematopoietic localization of CH and lymphoma-associated mutations in a cohort of patients with B-cell non-Hodgkin lymphomas (B-NHL). They observed a higher incidence of clonal mutations in the peripheral blood of patients with indolent B-cell lymphomas than in the peripheral blood of patients with aggressive B-cell lymphomas. Importantly, they show that disease-initiating clones are found in the stem/progenitor compartment in indolent B-NHLs and demonstrate clonal expansion in the B-cell lineage.
Volume 147, Issue 15
April 9 2026 A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia The putative KIT (multikinase) inhibitor dasatinib has shown promising results for the treatment of core-binding factor acute myeloid leukemia (CBF AML) in preclinical and small pilot studies. Döhner and colleagues report the results of a randomized phase 3 prospective clinical trial with chemotherapy-fit adults with CBF AML, comparing standard induction therapy to standard induction chemotherapy plus dasatinib. The addition of dasatinib to chemotherapy failed to improve event-free and overall survival in patients with CBF AML and appeared to increase toxicity. This negative study underscores the importance of randomized prospective clinical trials and puts to rest the use of dasatinib for CBF AML.
Volume 147, Issue 15
April 9 2026 Heat stress activates the coagulation cascade through Z-DNA-binding protein 1–dependent necroptosis Heatstroke is a life-threatening condition characterized by severe coagulation dysfunction. Li and colleagues report a new pathway of heat stress causing intravascular coagulation, mediated by a Z-DNA-binding protein 1–RIPK3–MLKL axis triggering cell death by necroptosis. This heat stress evokes necroptosis in myeloid cells, unleashing tissue factor (TF) activation through cell surface exposure of phosphatidylserine and triggering activation of the extrinsic pathway of coagulation via TF-carrying extracellular vesicles. This preclinical study reveals several new candidate targets for heatstroke therapy.
Volume 147, Issue 15
April 9 2026 Gastrin for the treatment of acute graft-versus-host disease of the stomach Gawron and colleagues, with a clever combination of human studies, stomach organoids, and mouse models of acute graft-versus-host disease (GVHD), report that GVHD disrupts the gastrin–cholecystokinin B receptor axis and leads to rapid loss of gastric stem cells. Pentagastrin treatment ameliorates immune injury and repairs stem and parietal cells, also at sites beyond the stomach. This work has the potential to influence the management of upper gastrointestinal GVHD by identifying disease-modifying therapies.
Volume 147, Issue 15
April 9 2026 Ring of fire cells: plasma cell–predominant relapse of Waldenström macroglobulinemia Volume 147, Issue 15
April 9 2026 CML mimicker: a myeloid neoplasm with BCR::FGFR1 fusion without peripheral blood eosinophilia or basophilia Volume 147, Issue 15
April 9 2026 Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011;117(19):5157-5165. Volume 147, Issue 15
April 9 2026 Volume 147, Issue 15
April 9 2026 |
Dabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum
Thu, 16 Apr 2026 23:14:51 -0700 Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience Thu, 16 Apr 2026 18:15:54 -0700 Real‐World Outcomes of Mycosis Fungoides and Site‐Specific Nodal Involvement: A Registry‐Based Study of 25 467 Patients Thu, 16 Apr 2026 04:29:15 -0700 The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors Wed, 15 Apr 2026 23:20:44 -0700 Accelerated Clonal Hematopoiesis and Premature Hematopoietic Aging in Benzene‐Exposed Populations Tue, 14 Apr 2026 18:45:06 -0700 Subtype‐Specific Risk of Non‐Melanoma Skin Cancers in MPN Patients: An Expanded Analysis of the MPN‐K Case–Control Database Tue, 14 Apr 2026 18:37:25 -0700 Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision‐Making Mon, 13 Apr 2026 18:24:58 -0700 Rapid HHV‐6 Clearance Following Preemptive Short‐Course Foscarnet in Allogeneic Stem Cell Transplant Recipients Mon, 13 Apr 2026 18:24:18 -0700 Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights Mon, 13 Apr 2026 00:00:00 -0700 Real‐World Outcomes in NPM1‐Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse Fri, 10 Apr 2026 05:35:42 -0700 A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B‐Cell Lymphoma Fri, 10 Apr 2026 02:57:26 -0700 Incidence of Hematologic and Solid Tumors in Adults With Sickle Cell Disease Fri, 10 Apr 2026 02:37:14 -0700 Somatic Mutations in Acquired Pure Red Cell Aplasia: Incidence and Implications Fri, 10 Apr 2026 02:36:28 -0700 Combination of Ocular Radiation With Systemic Chemotherapy for Treatment of Primary Vitreoretinal Lymphoma: A Prospective Single Center Cohort With Long Follow‐Up Fri, 10 Apr 2026 00:00:00 -0700 Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up Wed, 08 Apr 2026 00:00:00 -0700 Correction to “Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin (EPO) Due to EPO c.‐136 G>A Germline Mutation” Tue, 07 Apr 2026 20:40:29 -0700 Second Allogeneic Hematopoietic Cell Transplantation After Graft Failure Is an Effective Curative Option in Children With Hemoglobinopathies Tue, 07 Apr 2026 20:28:41 -0700 Critical Blue‐Green Neutrophilic Inclusions in the Context of CD19 CAR‐T Toxicity Tue, 07 Apr 2026 00:00:00 -0700 Magnetic Resonance Imaging as a Complementary Diagnostic Tool for Aplastic Anemia Tue, 07 Apr 2026 00:00:00 -0700 Hemophagocytic Macrophages in the Peripheral Blood of a Critically Ill Patient With COVID‐19 and RSV Infection Tue, 07 Apr 2026 00:00:00 -0700 Patients First: Navigating Asparaginase‐Based Treatment in Young Adults With Acute Lymphoblastic Leukemia Tue, 07 Apr 2026 00:00:00 -0700 |
|
|
| ||
|
Does age matter? Optimizing AML treatment in older adults March 24 2026 - Volume 10, Issue 6 Measure what matters: advocating for classical hematology’s future March 24 2026 - Volume 10, Issue 6 TLR8 gain-of-function: on the highway to the danger zone March 24 2026 - Volume 10, Issue 6 Advancing systems-based hematology March 24 2026 - Volume 10, Issue 6 A new era for heavy menstrual bleeding March 24 2026 - Volume 10, Issue 6 Reconsidering an age-old question March 24 2026 - Volume 10, Issue 6 Donor type outcomes in setting of PTCy: more apparent than real? March 24 2026 - Volume 10, Issue 6 The interplay of von Willebrand disease and women’s reproductive health March 24 2026 - Volume 10, Issue 6 American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults March 24 2026 - Volume 10, Issue 6 Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study March 24 2026 - Volume 10, Issue 6 Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma March 24 2026 - Volume 10, Issue 6 Foundations of systems-based hematology: thematic analysis of expert interviews to guide curriculums and promote growth March 24 2026 - Volume 10, Issue 6 Treatment of atypical hemolytic uremic syndrome and C3 glomerulopathy in mice by hepatic expression of factor D March 24 2026 - Volume 10, Issue 6 Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study March 24 2026 - Volume 10, Issue 6 Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel March 24 2026 - Volume 10, Issue 6 Infections after bispecific antibodies in B-cell lymphomas March 24 2026 - Volume 10, Issue 6 Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function March 24 2026 - Volume 10, Issue 6 Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial March 24 2026 - Volume 10, Issue 6 Hemoglobin binders reduce inflammation and tissue injury from hemolysis in venovenous extracorporeal circulation March 24 2026 - Volume 10, Issue 6 TNIK as a molecular switch regulating platelet function in hemostasis and hyperlipidemia-associated thrombosis March 24 2026 - Volume 10, Issue 6 Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice March 24 2026 - Volume 10, Issue 6 Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD March 24 2026 - Volume 10, Issue 6 Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years March 24 2026 - Volume 10, Issue 6 A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation March 24 2026 - Volume 10, Issue 6 Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients March 24 2026 - Volume 10, Issue 6 Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria March 24 2026 - Volume 10, Issue 6 Utilization patterns of hematology consultation in the intensive care unit: an 11-year single-center experience March 24 2026 - Volume 10, Issue 6 Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma March 24 2026 - Volume 10, Issue 6 Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia March 24 2026 - Volume 10, Issue 6 Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity March 24 2026 - Volume 10, Issue 6 Initial low and moderate dose of hydroxyurea has a durable impact on primary stroke prevention in low-income settings March 24 2026 - Volume 10, Issue 6 Loss of factor XIII decreases immune cell infiltration and enhances vessel wall endothelialization after venous thrombosis March 24 2026 - Volume 10, Issue 6 Rapid molecular response kinetics to anti-PD-1–based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial March 24 2026 - Volume 10, Issue 6 Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533-543. March 24 2026 - Volume 10, Issue 6 Paz DL, Gagelmann N, Benajiba L, et al. Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis. Blood Adv. 2025;9(4):797-807. March 24 2026 - Volume 10, Issue 6 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
|
|
| ||
|
|
Reply to “Interpreting lifetime alcohol intake and colorectal cancer risk”
Fri, 17 Apr 2026 01:51:10 -0700 Interpreting lifetime alcohol intake and colorectal cancer risk Thu, 16 Apr 2026 23:36:55 -0700 Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617 Baseline inflammatory markers are associated with clinical outcomes for patients treated with 177Lu–PSMA‐617. Thu, 16 Apr 2026 04:44:52 -0700 Health care discrimination and self‐reported health in transgender, gender nonconforming, and nonbinary individuals with cancer Thu, 16 Apr 2026 04:10:40 -0700 Assessing patient perspectives on enrollment in lymphoma clinical trials Thu, 16 Apr 2026 03:30:19 -0700 Correction to “The effect of common medications on the efficacy of immune checkpoint inhibitors” Wed, 15 Apr 2026 09:38:26 -0700 Factors influencing front line treatment of chronic lymphocytic leukemia: A French real‐world study Wed, 15 Apr 2026 06:30:11 -0700 Reply to “Comments on chemoradiotherapy in IDH wild‐type/TERT‐mutant grade 2/3 gliomas” Wed, 15 Apr 2026 00:05:52 -0700 Comments on chemoradiotherapy in IDH wild‐type/TERT‐mutant grade 2/3 gliomas Tue, 14 Apr 2026 23:49:20 -0700 A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer ASTX727 plus talazoparib produces significant myelosuppression without other adverse events. Modest methylation changes in PBMCs were detected. There were no objective responses, but some heavily pretreated patients had stable disease for >4 months despite the attenuated doses. Tue, 14 Apr 2026 10:33:18 -0700 Early cancer detection in a large American Cancer Society cohort study: Retrospective analysis of methylated DNA biomarkers Cancer signal detection rates change rapidly as lead time approaches clinical diagnosis. The average lead time of approximately 1 year supports annual screening intervals. Sun, 12 Apr 2026 21:42:49 -0700 Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry This study shows improved outcomes with the addition of TKI to chemotherapy and supports re‐classification of AML patients harboring BCR::ABL1 in the intermediate‐risk group. Nonetheless, given the small sample size, larger studies are needed to confirm these findings. Fri, 10 Apr 2026 04:09:05 -0700 Top advances of the year: Palliative and supportive care in oncology Thu, 09 Apr 2026 22:22:05 -0700 Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025 Thu, 09 Apr 2026 14:18:15 -0700 Treatment and outcomes of pulmonary mucosa‐associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients The OS of patients with MALT lymphoma with pulmonary involvement was favorable regardless of first‐line treatment modality, including watchful waiting. The short PFS in the stage IIE and IV groups indicates that these groups are candidates for therapeutic development. Thu, 09 Apr 2026 05:35:12 -0700 Aligning precision oncology with person‐centeredness: A call for a new definition Thu, 09 Apr 2026 04:31:54 -0700 Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status” Thu, 09 Apr 2026 04:26:30 -0700 Prognostic factors in neurofibromatosis type 1 (NF1)‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status Thu, 09 Apr 2026 04:02:11 -0700 Outcome of second‐line therapy in adult B‐cell acute lymphoblastic leukemia This study establishes a modern expectation of outcome of adult B‐cell ALL treated in salvage 1. Combination of chemotherapy and blinatumomab/inotuzumab should be a standard of care in adult B‐cell ALL in salvage 1. Thu, 09 Apr 2026 03:48:30 -0700 Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study‐3 and Circulating Cell‐Free Genome Atlas Substudy 3 These results provide estimates for average ctDNA detectable sojourn time in tumors across multiple cancer sites and stages and can inform the design of future screening studies for multicancer early detection. Thu, 09 Apr 2026 01:43:10 -0700 Issue Information Wed, 08 Apr 2026 23:51:45 -0700 |
|
|
| ||
|
|
|
|
|
| ||
|
Melanoma: Can AI Enable Diagnosis Prediction?
Assessment of machine-learning models tested on Swedish registry data enabled more accurate melanoma diagnosis prediction, with added health-care code, age, sex, and medication information for improved performance, according to the results of a study published in Acta Dermato-Venereologica. Friday, April 17, 2026 1:30 PM AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers Researchers have developed an artificial intelligence (AI) tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers scientists a clearer path to designing targeted therapies by showing which cells inside a tumor are most strongly... Friday, April 17, 2026 11:34 AM DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors A large prospective evaluation of off-label targeted cancer therapies has shown that more patients could potentially benefit from existing drugs. After including over 1,600 patients in the Dutch multicenter Drug Rediscovery Protocol (DRUP) trial (ClinicalTrials.gov identifier NCT02925234), the... Friday, April 17, 2026 11:10 AM Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC In a Chinese cohort study (OCEANUS) reported in JAMA Oncology, Zhou et al found that sequential radiotherapy (RT) and immune checkpoint inhibitor (ICI) therapy was associated with better overall survival vs concurrent RT and ICI therapy in patients with advanced newly diagnosed or refractory... Romiplostim for Chemotherapy-Induced Thrombocytopenia In a phase III trial (RECITE) reported in The New England Journal of Medicine, Al-Samkari et al found that the thrombopoietin receptor agonist romiplostim was effective in treating chemotherapy-induced thrombocytopenia (CIT) among patients receiving oxaliplatin-based multiagent cytotoxic... AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms About one in six survivors of an adolescent and young adult cancer will develop a subsequent primary neoplasm within 30 years of their original diagnosis, according to the results of a population-based study published in the Canadian Medical Association Journal. Thursday, April 16, 2026 10:45 AM Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma A population of patients with highly refractory follicular lymphoma achieved longstanding responses, with few significant adverse events, from odronextamab monotherapy, according to findings of the ELM-2 study. The study outcomes were published by Tessoulin et al in Clinical Lymphoma, Myeloma & ... Thursday, April 16, 2026 11:46 AM Is Standard of Care Optimal for the Individual Patient? I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. LuPSMA-617 and Pembrolizumab in mCRPC In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab showed “encouraging” activity in patients with metastatic castration-resistant prostate cancer (mCRPC). ASH/ISTH Create Guidelines for Pediatric VTE Prophylaxis The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have released a set of comprehensive clinical practice guidelines for the use of anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. The guidelines were... Wednesday, April 15, 2026 12:45 PM Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers Occupational exposure to asbestos-free talc did not increase the risk for lung, mesothelioma, or laryngeal cancers, according to the results of a systemic review and meta-analysis published in the Journal of Thoracic Oncology. Wednesday, April 15, 2026 11:30 AM New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia As reported in the Journal of Clinical Oncology, Lanino et al have developed a new model (international chronic myelomonocytic leukemia [CMML] prognostic scoring system [iCPSS]) for characterizing CMML by combining molecular information with clinical information. Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden Large language models performed better than physicians at producing accurate and comprehensive oncology pathology report summaries, according to the results of a study published in JCO Clinical Cancer Informatics. Tuesday, April 14, 2026 1:00 PM PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50% A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biopsy, according to first results from the phase III PRIMARY2 trial presented at the 2026 Annual... Wednesday, March 18, 2026 10:30 AM Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. Monday, April 6, 2026 10:00 AM Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring and care, according to findings published in Communications Medicine. Friday, April 3, 2026 11:30 AM Nancy L. Lewis, MD, MBS, FACP, Named NCCN’s New Chief Scientific Officer The National Comprehensive Cancer Network® (NCCN®) has announced the selection of Nancy L. Lewis, MD, MBS, FACP, as its new Chief Scientific Officer (CSO). Tuesday, April 14, 2026 10:43 AM Global Survival Index for Childhood Cancer: CONCORD-4 As reported in The Lancet, Allemani et al identified findings in the CONCORD-4 study indicating the degree of progress towards the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) target of 60% 5-year survival for all childhood cancers combined by the year 2030. Ablative Radiotherapy May Improve Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma A new study published by Jaoude et al in Clinical Cancer Research demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma. Tuesday, April 7, 2026 10:56 AM Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment Many people with lung cancer can be treated with a highly precise, high dose of radiation given in just one session without compromising the effectiveness of the treatment. The treatment strategy, outlined in a new publication authored by Singh et al in the International Journal of Radiation... Friday, April 3, 2026 10:51 AM Can Saying ‘I Do’ Reduce Cancer Risk? A U.S. population-based study across demographic groups and cancer types found that ever-married adults consistently had a lower cancer risk compared with never-married individuals. Published in Cancer Research Communications, these findings suggest that marital status may serve as a valuable... James P. Allison, PhD, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research The American Association for Cancer Research (AACR) will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to James P. Allison, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2026, to be held April 17-22 in San Diego. Monday, April 13, 2026 12:49 PM Electroacupuncture May Relieve Cognitive, Psychological Symptoms in Breast Cancer Survivors in Pilot Study Electroacupuncture may alleviate some persistent neuropsychiatric symptoms experienced by breast cancer survivors, including psychological distress and cognitive impairment, according to the results of a randomized, double-blinded pilot trial published in the Journal of the National Cancer... Monday, April 13, 2026 12:00 PM Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer Results from the OASIS 4 clinical trial showed that elinzanetant, a neurokinin-targeted therapy, relieved hot flashes and night sweats that can occur because of menopause or hormone treatment for breast cancer. These findings were published in June 2025 in The New England Journal of Medicine. Tuesday, March 31, 2026 10:00 AM POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a... Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients In a UK retrospective cohort study reported in The Lancet Oncology, Whitworth et al analyzed the frequency of germline genetic variants in patients with cancer in the 100,000 Genomes Project. |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
Myelodysplastic neoplasms (MDS) comprise a heterogeneous group of malignancies that can lead to ineffective haematopoiesis, cytopenias and, potentially, progression to acute myeloid leukaemia. In this Review, the authors describe the epidemiology of MDS, which appears to be rising, as well as advances in diagnosis, risk stratification and clinical management. Tue, 14 Apr 2026 00:00:00 -0700 Multidisciplinary management of meningiomas in the era of precision oncology Patients with meningioma, the most common type of intracranial primary tumour, have been traditionally managed with surgery and radiotherapy, although advances over the past decade have brought about promising novel treatment options. In addition, new molecularly driven classification tools can improve prognostic accuracy and guide personalized management decisions. The authors of this Review provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field. Mon, 13 Apr 2026 00:00:00 -0700 Cultivating the microbiome to enhance cancer immunotherapy Three recently published studies demonstrate the feasibility of modulating gut microorganisms using faecal microbiota transplantation (FMT) in patients receiving immune-checkpoint inhibitors (ICIs) in the first-line setting, expanding the evidence that FMT can augment response to ICIs. Herein, we discuss several opportunities for refining these efforts in order to increase the rigour and clinical benefit from microbiota modulation trials in oncology. Thu, 09 Apr 2026 00:00:00 -0700 A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles Cancer screening is an effective strategy for reducing cancer mortality, but in resource-constrained settings the key challenge is not simply whether screening works but how its implementation should be prioritized. We propose a framework for prioritizing cancer screening under resource constraints, summarized in three ‘not all’ principles: not all cancers are suitable for screening; not all individuals need screening; and not all high-performance technologies are appropriate for population screening. Thu, 26 Mar 2026 00:00:00 -0700 In what clinical settings are the MASAI trial results applicable? This Comment describes the clinical significance of the Mammography Screening with Artificial Intelligence (MASAI) trial, which is, to the best of our knowledge, the first randomized trial of artificial intelligence-supported mammography interpretation to examine interval cancer as an outcome. This trial used artificial intelligence to assign single-reading versus double-reading of mammograms and found that this approach does not increase interval cancers in the Swedish population. Tue, 24 Mar 2026 00:00:00 -0700 Neoadjuvant GOLP is effective in high-risk intrahepatic cholangiocarcinoma Neoadjuvant GOLP is effective in high-risk intrahepatic cholangiocarcinoma Wed, 18 Mar 2026 00:00:00 -0700 Author Correction: Innovative approaches for lung cancer screening and interception Author Correction: Innovative approaches for lung cancer screening and interception Tue, 10 Mar 2026 00:00:00 -0700 Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics The development of immune checkpoint inhibitors and novel targeted therapies and the incorporation of these agents into first-line therapy for biomarker-selected patients with metastatic gastric cancer has improved outcomes. Nonetheless, many challenges remain, including both primary and acquired resistance as well as a lack of relevant biomarkers in certain subgroups. In this Review, the authors describe the current approach to first-line therapy for patients with metastatic gastric cancer as well as emerging approaches that might improve the standard of care in the coming years. Tue, 10 Mar 2026 00:00:00 -0700 |
|
| ||
|
The association between adherence to elective nodal volume guidelines and reduced distant metastasis in esophageal and gastroesophageal junction cancer: a retrospective analysis of elective nodal irradiation
Vol 17, No 1 (February 28, 2026): Risk factors and prognostic implications of upper or middle mediastinal lymph nodes metastasis and recurrence in esophagogastric junction carcinoma Vol 17, No 1 (February 28, 2026): Identification and validation of an explainable machine learning model for early postoperative pulmonary complications after esophagectomy in patients with esophageal cancer Vol 17, No 1 (February 28, 2026): Private equity acquisitions of hospitals and the changing landscape of care for patients with gastrointestinal cancer Vol 17, No 1 (February 28, 2026): Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study Vol 17, No 1 (February 28, 2026): Training and validation of a nomogram for predicting synchronous distant organ metastasis in patients with very-early-onset colorectal cancer Vol 17, No 1 (February 28, 2026): Construction of taurine metabolism-related risk model and subtype identification in colorectal cancer to predict prognosis and immunological features Vol 17, No 1 (February 28, 2026): Non-surgical management of malignant bowel obstruction: strategies and outcomes in inoperable patients Vol 17, No 1 (February 28, 2026): A hybrid molecular-imaging model for high-accuracy early colorectal cancer diagnosis Vol 17, No 1 (February 28, 2026): A nine-gene nicotine-metabolism signature predicts prognosis and characterizes the immune landscape in colon adenocarcinoma Vol 17, No 1 (February 28, 2026): Overstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients Vol 17, No 1 (February 28, 2026): ColoLDB: a machine learning-based predictive model for colorectal cancer using routine laboratory parameters Vol 17, No 1 (February 28, 2026): Colon cancer cachexia remodels gut microbiota and metabolite profiles in a murine model Vol 17, No 1 (February 28, 2026): Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer Vol 17, No 1 (February 28, 2026): Association of fruit and vegetable consumption with colorectal adenoma among adults in Korea: a cross-sectional study Vol 17, No 1 (February 28, 2026): Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China Vol 17, No 1 (February 28, 2026): CPNE3 promotes colorectal cancer progression by regulating KIF4-mediated autophagy Vol 17, No 1 (February 28, 2026): The EZH2-NEAT1 epigenetic axis promotes cuproptosis sensitivity and modulates cancer cell migration in colorectal cancer Vol 17, No 1 (February 28, 2026): Short- and long-term outcomes after laparoscopic and open liver resection for combined hepatocellular-cholangiocarcinoma patients: a propensity score-matched study Vol 17, No 1 (February 28, 2026): Separation of liver focal nodular hyperplasia (FNH) and liver malignant tumors by a combination of T2-weighted imaging signal and three diffusion magnetic resonance metrics of diffusion-derived vessel density, slow diffusion coefficient, and apparent diffusion coefficient Vol 17, No 1 (February 28, 2026): Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 1 (February 28, 2026): ΔSII-based nomogram for prognosis prediction after radical resection for hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): Hedyotis diffusa Willd suppresses hepatocellular carcinoma tumor-stromal interactions by inactivating cancer-associated hepatic stellate cells Vol 17, No 1 (February 28, 2026): Clinical model for predicting overall survival outcomes in individuals with hepatocellular carcinoma: a retrospective cohort analysis Vol 17, No 1 (February 28, 2026): Global research trends and foci of ablation therapies for liver tumours: a scientometric study Vol 17, No 1 (February 28, 2026): FTSJ1-mediated IL1RN mRNA instability promotes inflammation-driven hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): Development and internal validation of a predictive nomogram for early postoperative bacterial infections following liver transplantation in patients with hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): Identification of mitochondrial-related subtypes and development of a prognostic model for pancreatic ductal adenocarcinoma Vol 17, No 1 (February 28, 2026): Real-world comparative effectiveness of FOLFIRINOX versus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer: prognostic impact of metastatic site and burden in a Middle Eastern cohort Vol 17, No 1 (February 28, 2026): The APOBEC3 family: a narrative review of an alternative therapeutic agent for hepatitis B virus-induced hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer Vol 17, No 1 (February 28, 2026): Partial splenic embolization plus antitumor therapy for treating patients with hepatocellular carcinoma and splenomegaly: a case series study Vol 17, No 1 (February 28, 2026): A case report: Masson’s tumor (intravascular papillary endothelial hyperplasia) of the abdominal cavity Vol 17, No 1 (February 28, 2026): Beyond LEAP-015: the ongoing challenge of vascular endothelial growth factor inhibition in gastric cancer Vol 17, No 1 (February 28, 2026): Checkpoint inhibition in advanced biliary tract cancer: progress, limitations, and the search for biomarker-driven strategies Vol 17, No 1 (February 28, 2026): The role of chemoradiotherapy after induction in locally advanced pancreatic cancer: lessons learnt from CONKO-007 Vol 17, No 1 (February 28, 2026): In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis? Vol 17, No 1 (February 28, 2026): Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges Vol 17, No 1 (February 28, 2026): Regorafenib in refractory gastric cancer: modest median, meaningful milestone Vol 17, No 1 (February 28, 2026): Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory? Vol 17, No 1 (February 28, 2026): Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study Vol 17, No 1 (February 28, 2026): Bevacizumab in biliary tract cancer: a clinical catalyst in the era of chemo-immunotherapy? Vol 17, No 1 (February 28, 2026): Biology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients Vol 17, No 1 (February 28, 2026): Retraction: HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis Vol 17, No 1 (February 28, 2026): |
|
|
|
| ||
|
Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation
Annals of Internal Medicine, Volume 179, Issue 3, Page 321-329, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Sodium Correction Rates and Associated Outcomes Among Patients With Severe Hyponatremia Annals of Internal Medicine, Volume 179, Issue 3, Page 330-339, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease Annals of Internal Medicine, Volume 179, Issue 3, Page 340-352, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Effect of Social Vulnerability on Efficacy of Bariatric Surgery Versus Medical and Lifestyle Intervention for Type 2 Diabetes: Analysis of the ARMMS-T2D Consortium of Randomized Trials Annals of Internal Medicine, Volume 179, Issue 3, Page 353-361, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Long-Term Mpox Sequelae 11 to 18 Months After Acute Illness Annals of Internal Medicine, Volume 179, Issue 3, Page 362-371, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Effects of a Hospital-Based Violence Intervention Program on Community Violence in Boston, Massachusetts Annals of Internal Medicine, Volume 179, Issue 3, Page 372-381, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 The Prevalence and Characteristics of Difficult Patient Encounters Annals of Internal Medicine, Volume 179, Issue 3, Page 382-393, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Addressing Primary Care Needs in People Living With Sickle Cell Disease Annals of Internal Medicine, Volume 179, Issue 3, Page 394-401, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Impact of Study Hypotheses on Results From Randomized Clinical Trials: Comparison Between Standard and Noninferiority Randomized Clinical Trials Annals of Internal Medicine, Volume 179, Issue 3, Page 402-410, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Primary Care Management of Chronic Kidney Disease Annals of Internal Medicine, Volume 179, Issue 3, Page 411-424, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Unexplained Pauses in Centers for Disease Control and Prevention Surveillance: Erosion of the Public Evidence Base for Health Policy Annals of Internal Medicine, Volume 179, Issue 3, Page 425-429, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 GRADE Guidance: Update on Developing Good Practice Statements in Guidelines Annals of Internal Medicine, Volume 179, Issue 3, Page 430-439, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 The Pharmaceutical Industry’s Quiet Win in the One Big Beautiful Bill Act Annals of Internal Medicine, Volume 179, Issue 3, Page 440-441, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Artificial Intelligence Scribes: Enhancing Workflow Efficiency at What Expense? Annals of Internal Medicine, Volume 179, Issue 3, Page 442-444, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Context Matters: Comparing the United States and Denmark in Vaccine-Preventable Disease Risk Annals of Internal Medicine, Volume 179, Issue 3, Page 445-446, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions Annals of Internal Medicine, Volume 179, Issue 3, Page 447-448, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 “Difficult Patients,” Persistent Symptoms, and the Biopsychosocial Model Annals of Internal Medicine, Volume 179, Issue 3, Page 449-450, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Tampering With Evidence: Selective Silencing of Timely Public Health Data Annals of Internal Medicine, Volume 179, Issue 3, Page 451-452, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Actionable and Evidence-Based Practice Statements: Can We Do Better? Annals of Internal Medicine, Volume 179, Issue 3, Page 453-454, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 The Problem of Suffering Annals of Internal Medicine, Volume 179, Issue 3, Page 455-456, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Behind the Seen: Searching for Peace in a House With Violence Annals of Internal Medicine, Volume 179, Issue 3, Page 457-458, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Misconceptions About Whether Seeking Mental Health Care Jeopardizes Lawful Firearm Ownership: A National Survey Annals of Internal Medicine, Volume 179, Issue 3, Page 462-464, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Rituximab Lymph Node Injection Combined With Angioplasty for Fibrosing Mediastinitis Annals of Internal Medicine, Volume 179, Issue 3, Page 464-466, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Reported Mammography Screening Interval by Age Among U.S. Women Annals of Internal Medicine, Volume 179, Issue 3, Page 466-467, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Reported Mammography Screening Interval by Age Among U.S. Women Annals of Internal Medicine, Volume 179, Issue 3, Page 467, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 Correction: Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 3, Page 467-468, March 2026. <br/> Tue, 13 Jan 2026 08:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
| ||
|
Allogene stock sails after CAR T clears residual lymphoma in early data cut
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.
Merck Pushes Winrevair Past Dose-Response Doubts Into Pivotal Study for Rare Type of Heart Failure The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair.
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze Therapeutics’ trial, according to Mizuho.
Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns Aardvark Therapeutics’ obesity asset is based on its lead molecule, which in February was linked to reversible heart safety signals in a healthy volunteer study.
Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026 Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic Encephalopathy Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026 ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15 Faron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDS TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation Antiva Biosciences Presents Data from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection at SGO 2026 Advances in Parkinson’s Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results |
Revolution rises 40% as pancreatic cancer drug doubles survival
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.
Viridian Turns Red as Thyroid Eye Disease Data Disappoint Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension, casting doubt on the asset’s future prospects.
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease AB Science provides an update on its clinical development program. Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026 ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026 BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100 TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI Meiji Seika Pharma’s Nacubactam to Be Featured in 10 Presentations at ESCMID Global 2026 — Including Phase III Integral-2 Results Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 Saphnelo® subcutaneous approved in Canada for the treatment of systemic lupus erythematosus Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer Lilly’s Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD |
Funding the future of European biotech
In this episode of Denatured, you’ll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there. Can Europe turn world-class science into world-class scale? Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter regulation and broader pools of patient capital to keep breakthrough companies growing at home.
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
Adopting a patient-centric approach is a competitive advantage Bringing patients into the drug development process early has proven to save time, money and resources.
Allogene stock sails after CAR T clears residual lymphoma in early data cut Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
Revolution rises 40% as pancreatic cancer drug doubles survival In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Your Scale, Your Terms: How Modular Bioreactors Are Redefining Capacity & Manufacturing Strategies Principal Scientist Anders Cai Holm Hansen explains how CDMO AGC Biologics uses its global, single-use network and a strategy emphasizing “scale-out” manufacturing, to derisk demand uncertainty, speed timelines and conserve cash for emerging drug developers.
GSK again pulls application for leucovorin, touted by FDA as potential autism treatment GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to treat cerebral folate deficiency with “autistic features.”
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is leaning on robotics, digital systems and partnerships to bridge the gap between innovation and delivery.
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™ Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026 Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic Encephalopathy Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 AB Science provides an update on its clinical development program. SEQSTER Launches 1-Click Sites™ to Transform Clinical Sites into Research-Ready Data Collection Points: Names BioIVT as First Deployment Partner /C O R R E C T I O N -- Boehringer Ingelheim/ Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026 Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026 ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug |
|
| ||
|
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:01 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:01 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:01 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:01 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:01 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:01 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:01 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:01 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:01 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:01 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:01 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:01 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:01 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:01 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:01 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:01 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:01 -0800
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
Wed, 19 Nov 2025 00:00:01 -0800
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Wed, 19 Nov 2025 00:00:01 -0800
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
Wed, 19 Nov 2025 00:00:01 -0800
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
Wed, 19 Nov 2025 00:00:01 -0800
FDA approves epcoritamab-bysp for follicular lymphoma indications On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
Tue, 18 Nov 2025 00:00:01 -0800
FDA approves new interchangeable biosimilar to Perjeta On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
Thu, 13 Nov 2025 00:00:01 -0800
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Thu, 13 Nov 2025 00:00:01 -0800
|
Are Clouds a Neglected Reservoir of Pesticides?
Environ Sci Technol. 2025 Oct 14;59(40):21579-21588. doi: 10.1021/acs.est.5c03787. Epub 2025 Sep 8. Bianco A, Nibert P, Wu Y, Baray JL, Brigante M, Mailhot G, Deguillaume L, Vione D, Cabanes DJE, Méjean M, Besse-Hoggan P Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026 Apr 16;394(15):1467-1479. doi: 10.1056/NEJMoa2513880. Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, van der Worp HB, Miglane E, Matijošaitis V, Lindgren AG, Sampaio Silva G, Sandset EC, Turuspekova ST, Amarenco P, Sheth KN, Smith EE, Eikelboom JW, Joundi RA, Schulze K, Xu L, Heenan L, Colorado P, Keller L, Muehlhofer E, Neumann C, Mundl H, Shoamanesh A; OCEANIC-STROKE Investigators Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2026 Apr 10:S0140-6736(26)00602-1. doi: 10.1016/S0140-6736(26)00602-1. Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X; ENGOT-ov65/KEYNOTE-B96 investigators The exploration of consciousness in insects. Philos Trans R Soc Lond B Biol Sci. 2025 Nov 13;380(1939):rstb20240302. doi: 10.1098/rstb.2024.0302. Epub 2025 Nov 13. Chittka L, Skeels S, Dyakova O, Janbon M Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. N Engl J Med. 2026 Apr 16;394(15):1480-1490. doi: 10.1056/NEJMoa2511478. Lin S, He Y, He L, Liu Y, Wang F, Xiong Z, Lin Y, Ye L, Chu C, Wang F, Zhao L, Cao Y, Zheng Y, Huang Q, Wang J, Liang X, Zhao Q, Sun S, Dou Y, He W, Huang X, Sun J, Huang X, Li Y, Liao Y, Lv H, Pan S, Zhu H, An X, He X, Zhao C, Liu X, Hu Y, Piao J, Qin L, Dong X, Peng Q, Wang C, Lin S, Huang P, Wu R, Peng H, Li Z, Wang D, Liu X, Yan W, Liu F, Huang G; Chinese Kawasaki Disease Collaboration Network Regulatory mechanism of miR-525-5p in over-invasion of trophoblast. J Obstet Gynaecol Res. 2021 Feb;47(2):679-688. doi: 10.1111/jog.14581. Epub 2020 Dec 1. Zhang M, Li P, Mao X, Zhang H Emotion regulation as mechanism of change in the treatment of depression - A latent change score analysis. J Affect Disord. 2026 Jan 1;392:120205. doi: 10.1016/j.jad.2025.120205. Epub 2025 Sep 2. Eichler E, Hager M, Baeuml J, Berking M Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2026 Apr 16;4(4):CD016297. doi: 10.1002/14651858.CD016297. Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E Protein-templated synthesis of dinucleotide repeat DNA by an antiphage reverse transcriptase. Science. 2026 Apr 16:eaed1656. doi: 10.1126/science.aed1656. Deng P, Lee H, Armijo C, Wang H, Gao A Tumor-derived branched-chain α-keto acids activate Notch signaling in tumor-associated macrophages to limit immunity. Nat Immunol. 2026 Apr 14. doi: 10.1038/s41590-026-02484-9. Ma QX, Zhao R, Han JX, Zhu WY, Xu MD, Zhang XY, Yan GQ, Wen WY, Han GC, Luo M, Yin M, Li JT, Lei QY Risks of adverse events for users of proton-pump inhibitors plus aspirin or clopidogrel in patients with aspirin-related ulcer bleeding. J Gastroenterol Hepatol. 2021 Jul;36(7):1828-1835. doi: 10.1111/jgh.15360. Epub 2020 Dec 11. Yang SC, Wu CK, Tai WC, Liang CM, Yao CC, Wu KL, Hsu CN, Chuah SK An evaluation of rehabilitation students' learning goals in their first year: a text mining approach. Front Med (Lausanne). 2024 Mar 13;11:1239916. doi: 10.3389/fmed.2024.1239916. eCollection 2024. Kitamura S, Takeda K, Uehara S, Yoshida T, Ota H, Tanabe S, Takeda K, Koyama S, Sakurai H, Kanada Y Cancer-Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT-ANGPTL4 Axis. Adv Sci (Weinh). 2026 Apr 14:e21418. doi: 10.1002/advs.202521418. Lu S, Ke S, Yu H, Meng Z, Bai M, Xu Y, Zhu H, Yang J, Qian B, Yin B, Wang C, Feng Z, Li Z, Zhou Y, Li Z, Li X, Hua Y, Fu Y, Tang W, Wu Y, Ma Y Rethinking ovarian cancer III: the past decade and future directions. Nat Rev Cancer. 2026 Apr 13. doi: 10.1038/s41568-026-00916-0. Balkwill FR, Laumont CM, Burdett N, Le Saux O, Garsed DW, Grither WR, Nijhuis AM, Recouvreux MS, Kang Z, Zhang R, Chiappinelli KB, Lee JS, Laniti DD, McNeish I, Ahmed AA, Rottapel R, Conejo-Garcia JR, Odunsi K, Pharoah PDP, Zamarin D, Ishak CA, Fotopoulou C, Buckanovich RJ, Labidi-Galy I, Brenton JD, Lengyel E, Cook DP, George SHL, Lheureux S, Drapkin R, Nephew KP, Adams S, Pathania S, Nelson BH, Färkkilä A, Fuh K, Neel BG, Bowtell DD Cell-type-targeted mitochondrial transplantation rescues cell degeneration. Nature. 2026 Apr 15. doi: 10.1038/s41586-026-10391-0. Ayupov T, Moreno-Juan V, Curtoni S, Fratzl A, Sharma U, Posada-Céspedes S, Ratiu R, Morikawa R, Meyer AG, Pezzoli M, Bantug G, Chevalier M, Hou Y, Nadeau SA, Herrero-Navarro Á, Ayinampudi V, Kastanaki E, Whitehead N, Siwicki RA, Ribeiro MM, Han JH, Bucci A, Hess C, Picelli S, Renner M, Müller DJ, Cowan CS, Hansen S, Roska B The 'window of opportunity' for death after severe brain injury: family experiences. Sociol Health Illn. 2013 Sep;35(7):1095-112. doi: 10.1111/1467-9566.12020. Epub 2012 Dec 20. Kitzinger J, Kitzinger C Somatic mosaicism in ALS and FTD identifies focal mutations associated with widespread degeneration. Nat Genet. 2026 Apr 15. doi: 10.1038/s41588-026-02570-6. Zhou Z, Kim J, Huang AY, Nolan M, Park J, Doan R, Shin T, Miller MB, Bae M, Zhao B, Kim J, Chhouk B, Morillo K, Yeh RC, Kenny C, Neil JE, Lee CZ, Ohkubo T, Ravits J, Ansorge O, Ostrow LW, Lagier-Tourenne C, Lee EA, Walsh CA Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk. N Engl J Med. 2026 Apr 16;394(15):1514-1528. doi: 10.1056/NEJMra2202438. Skeith L, Bates SM mRNA vaccines engage unconventional pathways in CD8+ T cell priming. Nature. 2026 Apr 15. doi: 10.1038/s41586-026-10353-6. Jo S, Li L, Thakur C, Telfer KA, Sultan H, Ohara RA, He M, Nam G, Chen J, Ou F, Draghi M, Valiante NM, Schreiber RD, Randolph GJ, Saligrama N, Murphy TL, Gillanders WE, Murphy KM Delayed acute capture myopathy in three roe deer. J Vet Med A Physiol Pathol Clin Med. 2002 Mar;49(2):93-8. doi: 10.1046/j.1439-0442.2002.jv409.x. Montané J, Marco I, Manteca X, López J, Lavín S |
|